Effects of SGLT2 Inhibitors as an Add-on Therapy to Metformin on Electrocardiographic Indices of Ventricular Repolarization

Basit Öğe Kaydı
dc.contributor.authorDuran, Mustafa
dc.contributor.authorZiyrek, Murat
dc.contributor.authorAlsancak, Yakup
dc.date.accessioned2024-02-23T14:44:48Z
dc.date.available2024-02-23T14:44:48Z
dc.date.issued2020
dc.departmentNEÜen_US
dc.description.abstractBackground: According to EMPA-REG OUTCOME, trial use of empagliflozin in patients with a history of cardiovascular disease improves hospitalization for heart failure and decreases cardiovascular morbidity and mortality. Recent studies have shown that a prolonged T-peak to T-end interval on the resting electrocardiography is associated with an increased risk of cardiovascular mortality. Tp-e/corrected QT interval (QTc) ratio is a reliable index of prolonged ventricular repolarization. Objectives: In this study, we examined the effects of sodium glucose co-transporters 2 (SGLT2) inhibitors as an add-on therapy to metformin on electrocardiographic indices of ventricular repolarization. Methods: Electrocardiographic recordings before combination therapy along with three months and six months follow-up of 141 consecutive patients who were switched from monotherapy to combination therapy with two oral agents due to inadequate glycemic control were derived. QT interval (QT), QTc, Tp-e intervals and Tp-e/QT, Tp-e/QTc ratios were calculated and analyzed. Results: After the six month follow-up, there was a significant decrease in the QT interval in patients who were using SGLT2 inhibitors as an add-on therapy to metformin compared to other glucose-lowering agents (373.4 +/- 9.9 ms vs. 385.4 +/- 12.5 ms, 382.9 +/- 11.2 ms; p < 0.001 respectively). Furthermore, Tp-e/QT and Tp-e/QTc ratios were significantly lower in this patient population compared to control groups (0.186 +/- 0.023 vs. 0.196 +/- 0.021, 0.191 +/- 0.017; p < 0.001 and 0.174 +/- 0.021 vs. 0.199 +/- 0.022, 0.195 +/- 0.016; p < 0.001 respectively). Conclusion: Our data showed that using SGLT2 inhibitors as an add-on therapy to metformin favorably alters ventricular repolarization indices in patients with type 2 diabetes mellitus.en_US
dc.identifier.doi10.6515/ACS.202011_36(6).20200511A
dc.identifier.endpage632en_US
dc.identifier.issn1011-6842
dc.identifier.issue6en_US
dc.identifier.pmid33235419en_US
dc.identifier.scopus2-s2.0-85096136101en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage626en_US
dc.identifier.urihttps://doi.org/10.6515/ACS.202011_36(6).20200511A
dc.identifier.urihttps://hdl.handle.net/20.500.12452/17124
dc.identifier.volume36en_US
dc.identifier.wosWOS:000591417800009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaiwan Soc Cardiologyen_US
dc.relation.ispartofActa Cardiologica Sinicaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDiabetes Mellitusen_US
dc.subjectRepolarizationen_US
dc.subject12-Lead Electrocardiogramen_US
dc.titleEffects of SGLT2 Inhibitors as an Add-on Therapy to Metformin on Electrocardiographic Indices of Ventricular Repolarizationen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu